

SPECIALTY GUIDELINE MANAGEMENT

Adbry (tralokinumab-ldrm)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendia uses are considered a covered benefit provided that all the approval criteria are met, and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

Adbry is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry can be used with or without topical corticosteroids.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

A. Initial requests:

- a. Member's chart notes or medical records showing affected areas and affected body surface area
- b. Member's chart notes or medical record documentation and claims history of prerequisite therapies including dosage, duration, and response to therapy. If therapy is not advisable, documentation of why therapy is not advisable.

B. Continuation requests: Documentation (e.g., chart notes) that the member has experienced a positive clinical response to therapy as evidenced by low disease activity or improvement in signs or symptoms of atopic dermatitis.

III. CRITERIA FOR INITIAL APPROVAL

Moderate-to-severe atopic dermatitis

Authorization of 4 months may be granted for treatment of moderate-to-severe atopic dermatitis when all of the following criteria are met:

1. Member is 18 years or older
2. Prescribed by, or in consultation with dermatologist or allergist/immunologist
3. Affected body surface is greater than or equal to 10% body surface area OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected
4. Member has tried and failed or had an inadequate response for at least 2-3 months to at least one medium-high to very high potency topical corticosteroid
5. Member has tried and failed or had an inadequate response for at least 2-3 months to pimecrolimus, tacrolimus ointment or crisaborole (Eucrisa)
6. Member has tried and failed or had an inadequate response for at least 6 months to cyclosporine, azathioprine, methotrexate, or mycophenolate mofetil
7. Member will not use Adbry concomitantly with other biologics or JAK inhibitors indicated for atopic dermatitis.

Effective Date: 8/1/2022
Reviewed: 06/2022, 06/2023
Scope: Medicaid

IV. CONTINUATION OF THERAPY

Moderate-to-severe atopic dermatitis

Authorization of 12 months may be granted for members 18 years of age or older who are using the requested medication for moderate-to-severe atopic dermatitis when both of the following are met:

- A. Member has achieved or maintained a positive clinical response with Adbry therapy evidenced by low disease activity (i.e., clear or almost clear skin), or improvement in signs and symptoms of atopic dermatitis (e.g., redness, itching, oozing/crusting).
- B. Member will not use Adbry concomitantly with other biologics or JAK inhibitors indicated for atopic dermatitis.

V. QUANTITY LIMIT/DOSAGE AND ADMINISTRATION

Adbry 150mg/ml : 4 syringes per 28 days or daily dose of 0.143 with an exception for the loading dose of 4 syringes per 14 days or daily dose of 0.29

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

VI. APPENDIX

Table. Relative potency of select topical corticosteroid products

Potency	Drug	Dosage form	Strength
I. Very high potency	Augmented betamethasone dipropionate	Ointment, Gel	0.05%
	Clobetasol propionate	Cream, Ointment	0.05%
II. High potency	Augmented betamethasone dipropionate	Cream, Lotion	0.05%
	Betamethasone dipropionate	Cream	0.05%
	Betamethasone valerate	Ointment	0.1%
	Fluocinonide	Ointment, Gel	0.05%
III. Medium potency	Triamcinolone acetonide	Cream, Ointment	0.5%
	Betamethasone dipropionate	Lotion	0.05%
	Betamethasone valerate	Cream	0.1%
	Fluocinolone acetonide	Cream, Ointment	0.025%
	Fluticasone propionate	Cream	0.05%
		Ointment	0.005%
IV. Low potency	Mometasone furoate	Ointment	0.1%
	Triamcinolone acetonide	Cream, Ointment, Lotion	0.025%, 0.1%
	Desonide	Cream	0.05%
	Fluocinolone acetonide	Cream, Solution	0.01%
	Hydrocortisone	Cream, Ointment	0.5%
		Cream, Ointment	1%
		Cream, Ointment	2.5%

VII. REFERENCES

Effective Date: 8/1/2022
Reviewed: 06/2022, 06/2023
Scope: Medicaid

1. Adbry [package insert]. Madison, NJ: LEO Pharma Inc.; May 2023.
2. Eichenfield LF, Tom WL, et. al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and Assessment of Atopic Dermatitis. *J Am Acad Dermatol*. 2014;70:338-51.
3. Utilization Management (UM) Criteria Review CVS Caremark P&T Subgroup. Dermatology – Biologic Agents – UM Criteria. April 2019.
4. Topical Corticosteroids. *Drug Facts and Comparisons*. Facts & Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health Inc; January 15, 2020. Accessed January 11, 2022.